PPARGC1β and CNTN4 Genotype Aspirin Study

Cardiovascular Diseases Clinical Trial

Official title:

PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02970604
• Other study ID #: RCSIMCT20152017
• Status: Recruiting
• Phase: Phase 4
• First received: November 18, 2016
• Last updated: November 18, 2016
• Start date: May 2016
• Est. completion date: February 2018

Study information

• Verified date: November 2016
• Source: Royal College of Surgeons, Ireland
• Contact: Kirstyn James, MB
• Phone: 0035318093706
• Email: kirsjames[@]rcsi.ie
• Is FDA regulated: No
• Health authority: Ireland: Health Products Regulatory Authority
• Study type: Interventional

Clinical Trial Summary

Heart attacks and strokes are common causes of death worldwide. These events occur in part, due to increased activity of platelets, which cause clotting (thrombosis) within heart and brain blood vessels.

Anti-platelet therapies (e.g. aspirin) reduce the likelihood of platelet thrombosis and therefore protect against heart attacks and strokes. However serious bleeding into the gut and brain occurs in a number of individuals prescribed aspirin. Currently, there is no reliable method for assessing the relative risks of thrombosis versus bleeding in individual patients prior to or during aspirin therapy.

We have recently discovered that individuals with a particular genetic make-up, those with genetic variants in two genes called PPARGC1β and CNTN4, demonstrate more active (sticky) platelets. We then found that these same individuals suffered a greater number of cardiovascular events. Interestingly, low dose aspirin suppressed the excessive platelet stickiness and protected against heart attacks and strokes in these patients.

In this project, we aim to confirm and extend the above findings. We hope that testing for PPARGC1β and CNTN4 genetic variants will allow us to identify which patients will benefit from low dose aspirin therapy - i.e. receive protection from heart attacks and strokes, but not suffer any bleeding complications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: February 2018
• Est. primary completion date: February 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must be male or female outpatients.

• Age must be greater than 18 years.

• Subjects must be able and willing to give written informed consent, and to comply with the requirements of this study protocol.

• Subjects must be at intermediate to high cardiovascular risk as determined by a calculated 5 year CVD risk of 5% or greater (calculated using the 1991 Anderson Framingham risk equation with adjustments as defined by the New Zealand Guidelines Group recommendations)

Exclusion Criteria:

• Age less than 18 years.

• Previous MI, stroke, transient ischaemic attack (TIA) or known CAD.

• Subjects who have any other significant disease or disorder (including concurrent malignancy) which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study.

• Known history of, or documented positive hepatitis B or C or HIV infection

• AST or ALT = 3 x ULN.

• Creatinine clearance (CrCl) < 60 mL/min measured by 24-hour urine collection or estimated by the Cockcroft and Gault formula.

• Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study, or with childbearing potential without using a medically accepted method of contraception (see notes 1-5 below)

• Patients already taking aspirin.

• Patients already taking anti-platelet agents (clopidogrel, ticagrelor etc), non-steroidal anti inflammatory drugs (NSAIDs), or anticoagulants (heparin, warfarin, dabigatran, etc).

• Patients who have a known intolerance to aspirin.

• Patients who have a contra-indication to aspirin as detailed below:

• Hypersensitivity to salicylic acid compounds or prostaglandin synthetase inhibitors (e.g. certain asthma patients who may suffer an attack or faint and certain patients who may suffer from bronchospasm, rhinitis and urticaria) and to any of the excipients.

• Active, or history of recurrent peptic ulcer and/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages.

• Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia.

• Patients who are suffering from gout.

• Severe hepatic impairment.

• Severe renal impairment.

• Patients taking methotrexate used at doses >15mg/week.

• History of peptic ulcer disease or upper gastrointestinal bleeding.

• Subjects who have a history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements.

• Participants unlikely to comply well with study treatments or with the scheduled visits.

• Scheduled for procedures requiring general anaesthesia during the study.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Cardiovascular Diseases

Intervention

Drug:
• Aspirin
Non enteric coated aspirin

Locations

Country	Name	City	State
Ireland	Royal College of Surgeons in Ireland	Dublin

Sponsors (1)

Lead Sponsor	Collaborator
Royal College of Surgeons, Ireland

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urinary Thromboxane B2/Creatinine Ratio		Baseline	No